Last reviewed · How we verify

Didrex (BENZPHETAMINE)

Pfizer · FDA-approved approved Small molecule Quality 41/100

Didrex (BENZPHETAMINE) is a sympathomimetic amine anorectic small molecule developed by PHARMACIA AND UPJOHN and currently owned by Pfizer. It targets the alpha-1A adrenergic receptor to treat obesity. Didrex was FDA-approved in 1960 and is now off-patent with multiple generic manufacturers. As a sympathomimetic amine, it works by stimulating the body's 'fight or flight' response to suppress appetite. Key safety considerations include its potential for abuse and dependence.

At a glance

Generic nameBENZPHETAMINE
SponsorPfizer
Drug classSympathomimetic Amine Anorectic
TargetAlpha-1A adrenergic receptor
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1960

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results